Hovedaktivitet har vært desinfeksjonsforsøk vha vår egenutviklede smittemodell. Et forsøk på å inaktivere virus med UV av ulike doser er gjennomført og med lovende resultat som nå skal gjentas. Inaktivering med klor vil da bli prøvd i parallell, med en modifisering av smittemateriale vi har utarbeidet etter de første forsøk med klor. Et hovedutfordring er å kunne lage virus-supensjon fra vev uten for mye organisk materiale som inaktiverer klor.
Vi har videre utviklet en isotermisk nukleinsyreamplifikasjo for SGPV med høy sensitivitet og som kan brukes i felt uten kostbart laboratorieutstyr. Den vil bli sammenliknet med eksisterende diagnostiske metoder mht anvendelighet. Sammen med en av næringspartnerne følger vi smittedynamikk og sykelighet over driftssyklus i et større anlegg, og relevant materiale for metodeutprøving blir da også inkludert.
Prosjektgruppen har hatt teamsmøter og diskutert framdrift og ny informasjon og blitt enig om hvordan en best kan løse utfordringene.
Recent studies show that salmon gill poxvirus disease has a wide distribution, is a significant welfare
problem and has a huge negative economical impact. The ongoing NRC fincanced project SALPOX
has resulted in a successful experimental model recreating salmon gill poxvirus disease opening
for studies that were previously impossible. Further, genotyping assay (MLVA), has been developed for studying the epizootiology of SGPV. This method has shown that within certain Norwegian fjord systems and individual freshwater salmon smolt farms in Norway, discrete MLVA clustering patterns that prevailed over time were observed. Many hatcheries experience recurrent outbreaks with SGPV disease, but despite screening of wild fish in the water sources and screening of hatcheries, we still do not know the reservoir of the virus or if salmon infected with SGPV become carriers of the SGPV. Apparently, as assessed from the results from pcr of gills form salmon that have survived an outbreak, they get rid of the virus. However, experiences from the field cannot rule out that such surviving salmon are in fact not shedding SGPV. TRACEPOX will benefit from support from MOWI ASA, SISOMAR AS, NOFIMA, Heilsufrøðiliga starvsstovan, Xylem, University of South- Eastern Norway as external partners and from already established platforms, SEC-TEQ where part of the aims is to provide tools for sequencing, more effective diagnostics and tracing and BioDirect focusing on establishment of biomarkers related to disease. TRACEPOX aims to find even more optimal ways to monitor and trace SGPV and to inactivate the virus, and thereby reduce losses and suffering caused by SGPV and secondary gill problems in the wake of SGPV. Further, to sharing experience on how to prevent a SGPVD outbreak and reduce suffering and death caused by SGPV.
